Trade

with

Data not available

Open

-

Previous Close

-

Volume (Avg)

-

Day's Range

-

52Wk Range

-

Market Cap.

-

P/E Ratio (EPS

-

Dividend Rate ( Yield )

-

Beta

-

Shares Outstanding

31.70M

P/E Ratio (EPS)

-

AdChoices
Financials
  • Income Statement
  • Balance Sheet
  • Cash Flow
Operating Income
-32.28M
Operating Margin
-
Total Equity
-
Retained Earnings
-
Free Cashflow
-
Price/Cashflow
-20.04
Ownership

Institutional Ownership

83.40%

Top 10 Institutions

69.88%

Mutual Fund Ownership

37.10%

Float

67.48%

5% / Insider Ownership

2.74%

Corporate insiders or major stockholders reporting trading activity in the stock.

Top Mutual Fund Owners

Top Institutional Owners

Mutual Fund Name

Institution Name

  • Mutual Fund Name

  • Shares Held

  • % Change

  • % Outstanding

  • VA CollegeAmerica Small Cap World

  •  

    1,628,457

  • 4.46

  • 5.14

  • Columbia Acorn Fund

  •  

    1,624,689

  • 0.00

  • 5.12

  • Fidelity® Select Biotechnology Portfolio

  •  

    1,087,727

  • 142.11

  • 3.43

  • American Funds IS® Gbl Sm Cap

  •  

    836,206

  • -3.46

  • 2.64

  • Fidelity® Select Health Care Portfolio

  •  

    562,900

  • 92.31

  • 1.78

  • Fidelity® Growth Company Fund

  •  

    517,600

  • 539.36

  • 1.63

  • BlackRock Health Sciences Opps Port

  •  

    386,105

  • 0.00

  • 1.22

  • Vanguard Small Cap Index

  •  

    329,899

  • 66.20

  • 1.04

  • Vanguard Total Stock Mkt Idx

  •  

    313,249

  • 67.76

  • 0.99

  • SPDR® S&P Biotech ETF

  •  

    296,076

  • 0.60

  • 0.77

  • Institution Name

  • Shares Held

  • % Change

  • % Outstanding

  • TPG Capital, L.P.

  •  

    3,085,240

  • 0.00%

  • 10.26

  • Capital Research Global Investors

  •  

    2,063,176

  • 0.00%

  • 6.86

  • Columbia Wanger Asset Management LLC

  •  

    1,793,182

  • -0.13%

  • 5.74

  • Adage Capital Partners Gp LLC

  •  

    1,756,968

  • -4.55%

  • 5.84

  • T. Rowe Price Associates, Inc.

  •  

    1,253,279

  • -9.90%

  • 3.98

  • Wellington Management Company, LLP

  •  

    624,579

  • -1.24%

  • 2.08

Company Profile

Sector

Healthcare

Industry

Biotechnology

Type

Distressed

Style

-

Ultragenyx Pharmaceutical Inc is a development-stage biopharmaceutical company engaged in identifying, acquiring, developing and marketing novel products for the treatment of rare and ultra-rare disease.

Key People

Dr. Emil D. Kakkis,M.D.

CEO/Director/President/Founder

Mr. Eran Nadav

Chairman of the Board/Director

Shalini Sharp

CFO/Senior VP

Mr. Michael P. Cohrs, PhD.

Vice President, Divisional

Mr. John Ditton

Vice President, Divisional

  • Ultragenyx Pharmaceutical Inc

  • 60 Leveroni Court

  • Novato, CA 94949

  • USA.Map

  • Phone: +1 415 483-8800

  • Fax: +1 415 483-8810

  • ultragenyx.com

Incorporated

2010

Employees

59

Send Feedback

We appreciate your input!

  • I'm having trouble signing into my Microsoft account

  • I’m having problems with the services stripe (Mail, Facebook, etc.)

  • There is an issue with my weather information

  • I see an error in the content

  • Other

Please give an overall site rating: